Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1-6 infection and compensated cirrhosis: the EXPEDITION-8 study [Abstract LB-7] | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1-6 infection and compensated cirrhosis: the EXPEDITION-8 study [Abstract LB-7]

Brown RS, Hezode C, Wang S, et al. Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1-6 infection and compensated cirrhosis: the EXPEDITION-8 study [Abstract LB-7]. The Liver Meeting. San Francisco, CA; 2018.

Publication Type:

Conference Proceedings

Authors:

Brown, RS; Hezode, Christophe; Wang, S; et, al

Source:

The Liver Meeting, San Francisco, CA (2018)

Cited On:

Export Citation:

RIS Format

Top